Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain

Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing

MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that ANJESO™ (meloxicam) injection, the only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory drug (NSAID), is now available for ordering and delivery to customers.

ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020 and is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

“We are delighted to announce the availability of ANJESO for ordering and delivery in the U.S.,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “These are challenging times for everyone involved in the delivery of healthcare in the United States and the well-being of everyone involved remains our top priority.

READ:  USA Technologies Elyssa Steiner to Speak at madconNYC Digital Marketing Summit

“I am pleased with the virtual outreach our current commercial team has been conducting and we believe ANJESO is a major advancement in the physician’s armamentarium for managing moderate to severe pain for a wide variety of surgical procedures.

“We are excited to offer this novel, non-opioid therapeutic option that has the potential to transform the acute pain treatment paradigm. We are diligently working to hire and train our field sales force and expect to execute the full ANJESO commercial launch by later in the 2nd quarter.”

ANJESO is administered as a once-a-day intravenous (IV) bolus push. ANJESO is the only available 24-hour, IV COX-2 preferential NSAID that offers once-daily dosing. The active ingredient meloxicam is a long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis.

READ:  Neuronetics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

For more information about ANJESO, visit or call 1-855-405-9983.

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee